C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in Grail, Inc. (NASDAQ:GRAL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,939 shares of the company's stock, valued at approximately $244,000.
Several other institutional investors and hedge funds also recently bought and sold shares of GRAL. Douglas Lane & Associates LLC bought a new position in Grail in the 4th quarter valued at $3,034,000. A. D. Beadell Investment Counsel Inc. purchased a new position in Grail in the 4th quarter worth about $430,000. FNY Investment Advisers LLC bought a new stake in Grail during the 4th quarter valued at about $26,000. 180 Wealth Advisors LLC bought a new stake in Grail during the 4th quarter valued at about $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management bought a new position in Grail in the 4th quarter worth about $387,000.
Grail Stock Performance
Grail stock traded down $7.03 during trading hours on Friday, reaching $40.73. The stock had a trading volume of 2,841,646 shares, compared to its average volume of 1,501,898. The business's 50 day moving average price is $26.32 and its 200-day moving average price is $19.06. Grail, Inc. has a 52 week low of $12.33 and a 52 week high of $63.99.
Grail (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.41) by $2.55. The firm had revenue of $38.25 million during the quarter, compared to analysts' expectations of $35.33 million. Research analysts expect that Grail, Inc. will post -65.16 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. Wolfe Research started coverage on shares of Grail in a research note on Friday, November 15th. They set a "peer perform" rating for the company. Morgan Stanley began coverage on Grail in a report on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 target price for the company.
Check Out Our Latest Analysis on Grail
Grail Company Profile
(
Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
See Also
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
